<DOC>
	<DOCNO>NCT02895815</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety CNTO 2476 cell administer subretinal space suprachoroidal surgical approach subretinal access kit ( SRAK-02 ) participant visual acuity impairment associate Geographic Atrophy ( GA ) secondary Age Related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>Efficacy Safety Study CNTO 2476 Participants With Visual Acuity Impairment Associated With Geographic Atrophy ( GA ) Secondary Age Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Participant suitable candidate ophthalmologic surgery , willing able comply surgical procedure , schedule visit , treatment plan , laboratory test study procedure . Participant meet criterion surgery center anti coagulation protocol , applicable Confirmed diagnosis geographic atrophy ( GA ) secondary agerelated macular degeneration ( AMD ) confirm within 28 day prior initial randomization central reading center use fundus photograph include follow ; ) The study eye must least 1 GA lesion involve fovea , Macular Photocoagulation Study ( MPS ) disc area ( DA ) &gt; = 1 &lt; = 7 ( 1 Macular Photocoagulation Study Disc Area ( MPS DA equivalent 2.54 millimeter ( mm ) ^2 retina ) determine screen image fundus autofluorescence photograph calculate reading center . If GA multifocal , least 1 lesion must &gt; = 0.5 DA , b ) GA must able photograph entirety may contiguous peripapillary atrophy , c ) Retinal photograph , fundus autofluorescence image , angiography sufficient quality , allow assessment macular area accord standard clinical practice , obtain ) The imaging center must able delineate confirm peripapillary atrophy fundus photography fundus autofluorescence , e ) Images must include central field 1 , 2 , 3 field image define University Wisconsin standard well supero temporal image capture subretinal injection area possible Female participant must postmenopausal last menses 12 month prior , long without medical reason ( example , treatment drug ) , measure follicle stimulate hormone &gt; = 26 milliinternational unit per milliliter ( mIU/mL ) Study eye best correct visual acuity ( BCVA ) 20/80 20/800 ( Early Treatment Diabetic Retinopathy Study ( ETDRS ) logMAR value 0.61.6 ) . BCVA study eye must worse BCVA fellow eye screen Male participant must sterile willing use 2 approve method contraception first day postoperatively 3 month postoperatively Participant history neovascular ( `` wet '' ) AMD study eye , include evidence retinal pigment epithelium rip evidence subretinal choroidal neovascularization . History evidence neovascular AMD fellow eye allow , antivascular endothelial growth factor ( VEGF ) therapy require least 8 week prior screen A diagnosis glaucoma intraocular pressure ( IOP ) &gt; = 25 millimeter mercury ( mm Hg ) treat ocular hypotensive drug . Treatment 1 drug preparation/combination , contain 1 2 ocular hypotensive active ingredient ; participant receive 2 ocular hypotensive active ingredient exclude Nuclear sclerotic cataract , cortical spoking , posterior subcapsular cataract Grade 2 per Age Related Eye Disease Study ( AREDS ) scale ophthalmologic condition reduces clarity medium , opinion investigator read center , interfere ophthalmologic examination ( example , corneal abnormality , inadequate pupillary dilation ) Myopia &gt; 8 diopter participant &gt; 4 diopter astigmatism , &gt; +10 diopter hyperopia Previous vitrectomy , retinal detachment repair , submacular surgery , surgical intervention target AMD , scleral buckling glaucoma filtration surgery extraocular orbital procedure study eye , opinion surgeon , would hamper suprachoroidal cannulation procedure study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>